



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

As of 03 March 2016, the Formulary Executive Council has recommended the **DISAPPROVAL** of the following medicines in the Philippine National Formulary:

**1. Pegylated Interferon alfa 2b 50 mcg, 80 mcg, 100 mcg, 120 mcg & 150 mcg Powder for Injection (SC)**

- Not included as either first or second line drug in the World Health Organization Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection (March 2015).
- It is currently not recommended because of the following factors: (1) moderate efficacy, (2) high cost, (3) availability as IV preparation, and (4) need to monitor for adverse effects.


**2. Cefuroxime suspension 250 mg/5 mL, 50 mL**

- For a five-day treatment regimen (5mL twice a day, as stated in the justification of the proponent), an exact volume will not allow buffer for potential spillage or wastage.

**3. Losartan potassium + Amlodipine camsylate 50mg/5mg, 100mg/5mg tablet**

- Cost of the fixed-dose combination (FDC) is very high (Php 27.00 to Php 30.00) compared to the total cost of the stand-alone preparations of losartan and amlodipine (Php 5.00)

Interested parties may submit their comments or request for reconsideration on or before 20 April 2016. Otherwise, appeals will no longer be entertained after the prescribed deadline.

  
**ANNA MELISSA S. GUERRERO, MD, MPH (HTA)**  
Division Chief  
Pharmaceutical Division  
Office for Health Regulations